Qiagen, Ventana settle dispute
This article was originally published in The Gray Sheet
Executive Summary
Qiagen (formerly Digene) and Ventana Medical settle their dispute over patents related to human papillomavirus tests Dec. 15. Ventana will pay an undisclosed cash amount. Qiagen is involved in ongoing disputes with other HPV test developers Third Wave Technologies and Roche (1"The Gray Sheet" Oct. 22, 2007, p. 22)
You may also be interested in...
Digene Fights Antitrust Charges As Part Of HPV Diagnostics Patent Case
Human papillomavirus test maker Digene, recently acquired by Qiagen, is defending itself against allegations of anti-competitive business practices from Third Wave Technologies as part of a larger patent battle between the firms
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.